Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer immunology research

• Publication date

  2016-12-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-16-0206PMID 28003187PMCID PMC5215959
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract LB-346: Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages

  2016cited by this paper
• VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma

  2016cited by this paper
• Abstract LB-347: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

  2016cited by this paper
• Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

  2015cited by this paper
• VEGF suppresses T‐lymphocyte infiltration in the tumor microenvironment through inhibition of NF‐κB‐induced endothelial activation

  2015cited by this paper
• Macrophages and cancer: from mechanisms to therapeutic implications.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Association of angiogenic factors with prognosis in esophageal cancer

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma

  2015cited by this paper
• Intertwined regulation of angiogenesis and immunity by myeloid cells.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

  2015cited by this paper
• Angiopoietin‐2: a multifaceted cytokine that functions in both angiogenesis and inflammation

  2015cited by this paper
• Immune Checkpoint Blockade in Cancer Therapy.

  2015cited by this paper
• Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

  2014cited by this paper
• Macrophage Colony-Stimulating Factor Augments Tie2-Expressing Monocyte Differentiation, Angiogenic Function, and Recruitment in a Mouse Model of Breast Cancer

  2014cited by this paper
• Tie2 Signaling Cooperates with TNF to Promote the Pro-Inflammatory Activation of Human Macrophages Independently of Macrophage Functional Phenotype

  2014cited by this paper
• Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Tumor-associated macrophages: from mechanisms to therapy.

  2014cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

  2014cited by this paper
• Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis

  2014cited by this paper
• Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.

  2014cited by this paper
• The M1 and M2 paradigm of macrophage activation: time for reassessment

  2014cited by this paper
• Human macrophage polarization in vitro: maturation and activation methods compared.

  2014cited by this paper
• Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

  2013cited by this paper
• Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.

  2013cited by this paper
• Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma

  2013cited by this paper
• A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors

  2013cited by this paper
• Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Macrophage regulation of tumor responses to anticancer therapies.

  2013cited by this paper
• The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway.

  2012cited by this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth

  2011cited by this paper
• Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

  2011cited by this paper
• Angiopoietin-2 promotes myeloid cell infiltration in a β₂-integrin-dependent manner.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

  2010cited by this paper
• Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions.

  2010cited by this paper
• Active immunotherapy induces antibody responses that target tumor angiogenesis.

  2010cited by this paper
• Targeting the ANGPT–TIE2 pathway in malignancy

  2010cited by this paper
• Macrophages, innate immunity and cancer: balance, tolerance, and diversity.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

  2010cited by this paper
• Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

  2009cited by this paper
• Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

  2009cited by this paper
• Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

  2009cited by this paper
• Angiopoietins: a link between angiogenesis and inflammation.

  2006cited by this paper
• Abstracts of the joint meeting of the Pathological Society of Great Britain and Ireland and the Dutch Pathological Society, 186th meeting of the Pathological Society of Great Britain and Ireland. 6-9 July 2004, Amsterdam, The Netherlands.

  2004cited by this paper
• Angiopoietins in tumours: the angiogenic switch

  2004cited by this paper
• VEGF as a mediator of tumor-associated immunodeficiency

  2001cited by this paper
• An application of changepoint methods in studying the effect of age on survival in breast cancer

  1999cited by this paper
• Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.

  1998cited by this paper
• Ang-2-vegf-a Crossmab, a Novel Bispecific Human Igg1 Antibody Blocking Vegf-a and Ang-2 Functions Simultaneously, Mediates Potent Anti-tumor, Anti-angiogenic, and Anti-metastatic Efficacy Financial Disclosure Translational Relevance on Lc06, an Ang-2 Selective Human Igg1 Antibody. the Potency of Ang

  year unknowncited by this paper

• Vessels encapsulating tumor clusters in hepatocellular carcinoma: a distinct metastatic pathway with diagnostic and therapeutic significance

  2026cites this paper
• Synergistic regulation of tumor angiogenesis via flavonoid modulation of lncRNAs: Mechanistic insights and therapeutic potential.

  2026cites this paper
• Hsa_circ_0005623 is an indicator for pulmonary artery hypertension associated with congenital heart disease

  2026cites this paper
• Angiogenic Edge of ANGPT2: Genetic Variants Shape Prostate Cancer Prognosis on Androgen Deprivation Therapy

  2025cites this paper
• Dual faces of angiogenesis: Mechanisms and therapeutic applications.

  2025cites this paper
• MAPK signaling and angiopoietin-2 contribute to endothelial permeability in capillary malformations.

  2025cites this paper
• Developing of potential mRNA vaccines based on tumor antigens and immune subtypes of esophageal cancer

  2025cites this paper
• Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer

  2025cites this paper
• MAPK Signaling and Angiopoietin-2 Contribute to Endothelial Permeability in Capillary Malformations

  2025cites this paper
• The role of innate immune cells in modulating vascular dynamics in skin malignancies.

  2025cites this paper
• Bioengineering a Patient‐Derived Vascularized Lung Tumor‐on‐Chip Model to Decipher Immunomodulation by the Endothelium

  2025cites this paper
• Recent advances in novel tumor immunotherapy strategies based on regulating the tumor microenvironment and immune checkpoints

  2025cites this paper
• Super enhancers as Drivers of Hallmarks of Cancer: From Oncogene Activation to Metastatic Progression.

  2025cites this paper
• Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma

  2025cites this paper
• Integrated pan-cancer and melanoma-specific analysis of angiopoietin-2: prognostic value, immune microenvironment modulation, and ceRNA network regulation

  2025cites this paper
• Specificity and kinetics of human candidate cerebral malaria biomarkers in mice

  2025cites this paper
• Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies

  2025cites this paper
• Current and novel biomarkers in cardiogenic shock

  2025cites this paper
• Multi-omics analysis of macrophage-associated receptor and ligand reveals a strong prognostic signature and subtypes in hepatocellular carcinoma

  2024cites this paper
• A Phase 1 Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer.

  2024cites this paper
• The Role of Dopamine in Gastric Cancer—A Systematic Review of the Pathogenesis Phenomena Developments

  2024cites this paper
• The CLCF1-CNTFR axis drives an immunosuppressive tumor microenvironment and blockade enhances the effects of established cancer therapies

  2024cites this paper
• Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review

  2024cites this paper
• Significance of expression of PD-L1, VEGF and CD8+ T cells in ovarian serous carcinoma: an Immunohistochemical study

  2023cites this paper
• Targeting vascular normalization: a promising strategy to improve immune–vascular crosstalk in cancer immunotherapy

  2023cites this paper
• Alleviating hypoxia to improve cancer immunotherapy

  2023cites this paper
• Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

  2023cites this paper
• EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade

  2023cites this paper
• Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance.

  2023cites this paper
• Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses

  2023cites this paper
• Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models

  2023cites this paper
• Immune checkpoint inhibitor–associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study

  2023cites this paper
• Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages

  2023cites this paper
• Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.

  2023cites this paper
• Transcriptomic Establishment of Pig Macrophage Polarization Signatures

  2023cites this paper
• Homeobox D9 drives the malignant phenotypes and enhances the Programmed death ligand-1 expression in non-small cell lung cancer cells via binding to Angiopoietin-2 promoter

  2023cites this paper
• Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer.

  2023cites this paper
• A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma

  2023cites this paper
• Single-cell pair-wise relationships untangled by composite embedding model

  2023cites this paper
• Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy

  2022influential citation
• Nano-targeting Vascular Remodelling in Cancer: Recent Developments and Future Directions.

  2022cites this paper
• Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

  2022cites this paper
• Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade

  2022cites this paper
• The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment

  2022cites this paper
• Emerging technologies for genetic control systems in cellular therapies.

  2022cites this paper
• Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma

  2022cites this paper
• Antiangiogenic drugs as chemosensitizer in melanoma

  2022cites this paper
• Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial cells into quasi-antigen-presenting cells

  2022cites this paper
• Systemic Immune Inflammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy.

  2022cites this paper
• A pan-cancer analysis reveals the genetic alterations and immunotherapy of Piezo2 in human cancer

  2022cites this paper
• Ang2-Targeted Combination Therapy for Cancer Treatment

  2022cites this paper
• Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact

  2022cites this paper
• Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

  2021cites this paper
• Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer

  2021cites this paper
• Cancer immunotherapy: it’s time to better predict patients’ response

  2021cites this paper
• Identification of novel drug resistance mechanisms by genomic and transcriptomic profiling of glioblastoma cells with mutation-activated EGFR.

  2021cites this paper
• Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer

  2021cites this paper
• Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

  2021cites this paper
• Next generation of immune checkpoint inhibitors and beyond

  2021cites this paper
• Cancer vaccines: an unkept promise?

  2021cites this paper
• IFN-γ and CD38 in Hyperprogressive Cancer Development

  2021cites this paper
• Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

  2021cites this paper
• Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade

  2021cites this paper
• Anti-melanoma effects of concomitant inhibition of SIRT1 and SIRT3 in BrafV600E/PtenNULL mice.

  2021cites this paper
• Pan-Cancer Analysis of PIMREG as a Biomarker for the Prognostic and Immunological Role

  2021cites this paper
• In Uveal Melanoma, Angiopoietin-2 but Not Angiopoietin-1 Is Increased in High-Risk Tumors, Providing a Potential Druggable Target

  2021cites this paper
• NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

  2021influential citation
• Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade

  2021cites this paper
• Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression

  2021cites this paper
• Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment

  2021cites this paper
• Laboratory biomarkers of an effective antitumor immune response. Clinical significance.

  2021cites this paper
• Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges

  2021cites this paper
• Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors

  2021cites this paper
• Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy

  2020cites this paper
• Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response

  2020cites this paper
• The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.

  2020cites this paper
• Angiopoietin-2 as a Prognostic Factor in Patients with Incurable Stage IV Colorectal Cancer

  2020cites this paper
• Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy

  2020cites this paper
• Small Molecular Immune Modulators as Anticancer Agents.

  2020cites this paper
• Dissection of prostate tumour, stroma and immune transcriptional components reveals a key contribution of the microenvironment for disease progression

  2020cites this paper
• Blocking Angiopoietin-2 Promotes Vascular Damage and Growth Inhibition in Mouse Tumors Treated with Small Doses of Radiation

  2020cites this paper
• Tumor-on-a-chip platform to interrogate the role of macrophages in tumor progression

  2020cites this paper
• Association of Genetic Variants in ANGPT/TEK and VEGF/VEGFR with Progression and Survival in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy or Radiochemotherapy

  2020cites this paper
• Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade

  2020cites this paper
• VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer

  2020cites this paper
• Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment

  2020cites this paper
• Effect of Chitosan Magnetic Nanoparticles Loaded with Ang2-siRNA Plasmids on the Growth of Melanoma Xenografts in Nude Mice

  2020cites this paper
• RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?

  2020cites this paper
• Hyperprogression: A novel response pattern under immunotherapy

  2020cites this paper
• Neoangiogenesis in Melanoma: An Issue in Biology and Systemic Treatment

  2020cites this paper
• The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma

  2020cites this paper
• Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance

  2020cites this paper
• Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

  2020cites this paper
• Pan-Cancer Analysis of the Mitophagy-Related Protein PINK1 as a Biomarker for the Immunological and Prognostic Role

  2020cites this paper
• A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy

  2020cites this paper
• Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy

  2020cites this paper
• The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer

  2020cites this paper
• Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer

  2020cites this paper
• Immunopathology and Immunotherapy for Breast Cancer

  2020cites this paper
• CMAR_A_250479 7475..7485

  2020cites this paper